share_log

Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?

Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?

Intra-Cellular Therapies股票在週一急劇上漲:發生了什麼?
Benzinga ·  01/13 19:58

Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company.

Intra-Cellular Therapies Inc.(納斯達克:ITCI)的股票在週一上漲,此前強生同意收購該公司。

What To Know: Johnson & Johnson on Monday entered into a definitive agreement to acquire all outstanding shares of Intra-Cellular Therapies for $132 per share in cash in a deal that values the company at approximately $14.6 billion.

強生在週一達成了一項最終協議,將以每股132美元的現金收購所有流通中的Intra-Cellular Therapies股份,此交易的公司估值約爲146億。

The acquisition is expected to strengthen Johnson & Johnson's presence in neuroscience, and includes Intra-Cellular Therapies' CAPLYTA (lumateperone), a once-daily oral treatment approved by the FDA for schizophrenia and depressive episodes linked to bipolar I and II disorder.

此項收購預計將加強強生在神經科學領域的地位,幷包括Intra-Cellular Therapies的CAPLYTA(lumateperone),這是一種每天一次口服治療藥物,已獲得FDA批准用於治療精神分裂症和與雙相障礙I和II相關的抑鬱發作。

Johnson & Johnson also gains a pipeline, including ITI-1284, which is being tested for generalized anxiety disorder and Alzheimer's-related psychosis and agitation.

強生還獲得了一條藥物研發管線,包括正在測試的ITI-1284,該藥物用於廣泛性焦慮症和與阿爾茨海默症相關的精神病和激動。

In December 2024, Intra-Cellular Therapies submitted a supplemental new drug application for CAPLYTA as an adjunctive treatment for major depressive disorder. If approved, the drug could become a key player in treating common depressive disorders, potentially generating over $5 billion in annual sales.

在2024年12月,Intra-Cellular Therapies提交了一項補充新藥申請,申請CAPLYTA作爲重度抑鬱症的輔助治療。如果獲得批准,該藥物有望成爲治療常見抑鬱症的重要藥物,年銷售額可能超過50億。

The transaction is expected to close later this year, pending regulatory and shareholder approvals. Once completed, Intra-Cellular Therapies' stock will be delisted from the Nasdaq. Johnson & Johnson plans to fund the acquisition with cash on hand and debt. Johnson & Johnson is also expected to provide commentary on any potential impact to adjusted earnings when it reports financial results on Jan. 22.

該交易預計在獲得監管和股東批准後於今年晚些時候完成。一旦完成,Intra-Cellular Therapies的股票將從納斯達克退市。強生計劃通過現有現金和債務資助此次收購。強生還預計在1月22日報告財務結果時對調整後的收益可能產生的影響提供評論。

ITCI Price Action: Intro-Cellular shares were up 34.2% at $127.27 at the time of writing Monday, according to Benzinga Pro.

ITCI價格動態:根據Benzinga Pro的數據,在編寫時,Intro-Cellular的股價上漲了34.2%,達到了127.27美元。

big
  • ON Semi Sees Utilization Cuts As EV Demand Softens, Analyst Warns
  • ON Semiconductor因電動車需求減弱而看到產能削減,分析師警告

Photo by solarseven on Shutterstock.

Shutterstock上solarseven拍攝的照片。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 337

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。